NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
18/06/2024
Voltar para busca
Dado oficial do USPTO
CELLCARTA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CELLCARTA
ST13
US500000090112472Classe
42, 44, 45
Pedido
90112472
Registro
7422358
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
44
Atualização mais recente
18/06/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42, 44, 45
Data de depósito
13/08/2020
Data de registro
18/06/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
18/06/2024
Última transação
18/06/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
2021-03-00
Primeiro uso no comércio
2021-03-00
Código do desenho
4
Tipo de titular
03
Localização do titular
MONTREAL, QUEBEC, CA
Examinador
LEE, OLIVIA SUNMIN
Unidade examinadora
O10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
CELLCARTA BIOSCIENCES INC.
Caprion Biosciences, Inc.
Representantes
Keith Toms, Esq. MCCARTER & ENGLISH, LLP
Classificação técnica
Classes Nice
Classe 42Classe 44Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Scientific research and development; Medical research and development; Product research and development; Biochemical research and development; Pharmaceutical research and development services; Biomedical research and development services; Design and development of biochemicalpharmaceuticalmedical assays; Scientific and pharmaceutical research in the field of biomarker discovery; Scientific research and development in the fields of bioinformaticsbiomarkersgenomicsproteomicsgenotypingpathologyhistopathology; immune monitoringgenetic profiling for research and development purposes; scientific research and development in the field of mass cytometrycellular analysiscell sortingpathway phenotypingmolecular surface profiling; custom design and development of chemical reagents and biochemical assays; medical laboratory services in the field of pathology; providing laboratory testing services in the fields of bioinformaticsbiomarkersgenomicsproteomicsgenotypingpathologyhistopathology; Conducting clinical trials for others; Conducting clinical trials for others in the fields of pharmaceuticalmedicalscientific research; Consulting services for others in the field of designplanningimplementation project management of clinical trials; Conducting research and clinical trials for others in the fields of oncologyinfectious diseasesautoimmune disordersallergies; Consulting services in the field of clinical trial research; Providing medical and scientific research information in the field of clinical trials; Research and development in the pharmaceutical and biotechnology fields; Laboratory research services relating to pharmaceuticals; Software as a service (SAAS) services featuring software for informaticsbioinformatics; software as a service (SAAS) services featuring software for clinical trial data acquisitionvalidationanalysis; Software as a service (SAAS) services featuring software for cellular analysiscell sortingpathway phenotypingmolecular surface profiling; Software as a service (SAAS) services featuring software for cell cytometry; Software as a service (SAAS) services featuring software for managing information related to clinical trials
Classe 44
Genetic testing for medical purposes; Consulting services in the fields of diagnostic medical testing; Medical testing for diagnostic or treatment purposes; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; providing medical information and advice in the fields of pathologypharmacologyimmunology; collectionorganizationanalysisreporting of medical data in connection with clinical and non-clinical trials and studies on pharmaceuticals and medical devices; immune monitoringgenetic profiling for medical and diagnostic purposes
Classe 45
Regulatory compliance consulting in the fields of pharmaceuticals and clinical diagnostics; Advice and consultancy on fooddrugmedical device regulatory matters; regulatory compliance consulting in the field of obtaining government authorization to market pharmaceuticals and medical device
Publicações
Histórico de despachos e eventos da marca no USPTO.
44 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
18/06/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
13/05/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
13/05/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
19/03/2024
IUAF
USE AMENDMENT FILED
18/03/2024
EISU
TEAS STATEMENT OF USE RECEIVED
18/03/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
20/09/2023
EX5G
SOU EXTENSION 5 GRANTED
19/09/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
19/09/2023
EXT5
SOU EXTENSION 5 FILED
12/09/2023
EEXT
SOU TEAS EXTENSION RECEIVED
12/09/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
14/03/2023
EX4G
SOU EXTENSION 4 GRANTED
10/03/2023
EXT4
SOU EXTENSION 4 FILED
10/03/2023
EEXT
SOU TEAS EXTENSION RECEIVED
10/03/2023
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
01/02/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
20/09/2022
EX3G
SOU EXTENSION 3 GRANTED
16/09/2022
EXT3
SOU EXTENSION 3 FILED
16/09/2022
EEXT
SOU TEAS EXTENSION RECEIVED
16/09/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
17/03/2022
EX2G
SOU EXTENSION 2 GRANTED
15/03/2022
EXT2
SOU EXTENSION 2 FILED
15/03/2022
EEXT
SOU TEAS EXTENSION RECEIVED
15/03/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
18/09/2021
EX1G
SOU EXTENSION 1 GRANTED
16/09/2021
EXT1
SOU EXTENSION 1 FILED
16/09/2021
EEXT
SOU TEAS EXTENSION RECEIVED
16/09/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
16/03/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/01/2021
PUBO
PUBLISHED FOR OPPOSITION
19/01/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/12/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/12/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
11/12/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/12/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
11/12/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/12/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/12/2020
GNRT
NON-FINAL ACTION E-MAILED
09/12/2020
CNRT
NON-FINAL ACTION WRITTEN
09/12/2020
DOCK
ASSIGNED TO EXAMINER
08/12/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
17/09/2020
NWAP
NEW APPLICATION ENTERED
17/08/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CELLCARTA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.